Area of research
Immunology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, T-cell and B-cell Immunology, and Hematopoietic Stem Cell Transplantation.
Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma
Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma
Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing
Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Production and Application of CAR T Cells: Current and Future Role of Europe
Gene Therapy “Made in Germany”: A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation
CAR-Expressing Natural Killer Cells for Cancer Retargeting
Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering
Development of adaptive immune effector therapies in solid tumors
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer–Based “Off-the-Shelf” Acute Myeloid Leukemia Immunotherapies
Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease
Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved <i>Ex Vivo</i> Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma
Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies
Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L <sup>+</sup> T Cells for Manufacturing of Gene Therapy Medicinal Products
T‐lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover
Advantages and applications of CAR-expressing natural killer cells
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors
5-Lipoxygenase Is a Direct Target of miR-19a-3p and miR-125b-5p
Lentivirus-induced ‘Smart’ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma
Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells